patel dinesh president arete therapeutics  spoke login register add company add person add topic login or home  people  patel dinesh advanced search faq javascript is disabled bio edit patel dinesh alias or nickname president arete therapeutics davis ca find other people named patel dinesh general info rd in biotech environmental and various industries no marketing product yet add tags— eg finance businessbusiness dinesh v patel phd president and ceoformer president coo  cofounder of miikana therapeutics  acquired by entremed in  sr vp of drug discovery  licensing at vicuron  acquired by pfizer in  director at affymax  acquired by gsk in  group leader medicinal chemistry at bristolmyers squibb  not who youre looking for find other patel dineshes on spoke contact telephone email background report public records powered by digital info wwwaretetherapeuticscom na na na na na na resume edit career arete therapeutics president education edit add a degree— eg bachelors in business administration blogs by industry voices there are currently no blogs by industry voices achievements and recognition edit add an achievement andor recognition— eg man of the year forbes  notable links edit the links below are powered by bing search results click edit to customize videos edit add a videofrom youtube or vimeo executives  featured people at arete therapeutics bruce hammock chairman hal barron senior vp of development dinesh patel president yi jim director pharmacology james bristol scientific and strategic advisor richard lin partner heather webb director of drug safety created on jun   by spoke   edited on jun   by spoke   page completion  industry career websiteblog summary add  notable links add  achievements add education add a video add a photo add a social network view more view less share this page add page add company add person add topic copy this code to embed a widget div idspokerootdiv scriptfunctiond s id document script spokewidgetjsscript div classspokewidget datahostwwwspokecom datatypeperson dataidececacda datawidth dataheight datascrollno dataframebordernonediv div stylefontsize pta hrefhttpwwwspokecompeoplepateldineshececacdapatel dinesha widget provided by a hrefhttpwwwspokecomspokeadiv public records our partner can help you find public records for patel more on some of spokes content providers become a spoke content provider learn more dinesh v patel phd executive profile  biography  bloomberg july    am et biotechnology company overview of protagonist therapeutics inc snapshotpeople  overviewboard memberscommittees executive profile dinesh v patel phdchief executive officer president secretary and director protagonist therapeutics incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationshipsas of fiscal year  background dr dinesh v patel phd has been the chief executive officer and president at protagonist therapeutics inc since december  dr patel serves as secretary of protagonist therapeutics inc dr patel served as consultant of arête therapeutics inc since july  he served as chief executive of arête therapeutics inc from february  to july  and also served as its president until july  dr patel cofounded miikana therapeutics inc in  served  as its president and chief operating officer he served as senior vice president of drug discovery and licensing of vicuron pharmaceuticals inc formerly versicor until july  dr patel has over  years of experience in the pharmaceutical biotech and biopharmaceutical industry he was part of the senior management team that incubated versicor on the us west coast in  as a spinoff from sepracor at versicor he led their internal and collaborative research programs pharmacia novartis and actively participated in various financing activities dr patel served as director of drug discovery of affymax and led the combinatorial chemistry application efforts aimed at changing the drug discovery paradigm he also worked at bristolmyers squibb for eight years in various positions including group leader dr patel has a proven track record of incubating and leading projects from ‘targets to inds’ he serves as a director of protagonist therapeutics inc he served as director of arête therapeutics inc until july  he has more than  patents and publications to his credit dr patel received his phd in organic chemistry from rutgers the state university of new jersey and conducted postdoctoral research at the university of wisconsin madisonread full background corporate headquarters  cottonwood drivemilpitas california united statesphone fax  board members memberships chief executive officer president secretary and directorprotagonist therapeutics inc education postdoctoral training university of wisconsin  madisonphd rutgers the state university of new jersey other affiliations vicuron pharmaceuticals incuniversity of wisconsin  madisonrutgers the state university of new jerseymiikana therapeutics incarête therapeutics inc annual compensation salarytotal annual compensation stocks options exercisable optionsunexercisable optionstotal number of options total compensation total annual cash compensationtotal short term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact protagonist therapeutics inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close dinesh v patel phd  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in dinesh v patel phd dir president and chief executive officer at protagonist therapeutics view full profile are you dinesh v patel phd claim your profile   sign up for equilar atlas and view dinesh v patel phds full profile with equilar atlas you can identify corporate executives in dinesh v patel phds network and community follow changes in dinesh v patel phds employment and moneyinmotion connect with dinesh v patel phd through your network of contacts dinesh v patel phds executive work history current dir president and chief executive officer protagonist therapeutics past to view dinesh v patel phds complete executive work history sign up now age      sign up for equilar atlas and view dinesh v patel phds full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like dinesh v patel phd more specifically youll be able to identify corporate executives in dinesh v patel phds network and community follow changes in dinesh v patel phds employment and moneyinmotion connect with dinesh v patel phd through your network of conections view full profile   search for over  executive profiles bio example dinesh v patel phd dinesh v patel phds connections  sign up now to view dinesh v patel phds  connections » julie papanek board member protagonist therapeutics david y liu chief scientific officer protagonist therapeutics william a hodder senior vice president corporate development protagonist therapeutics harold e selick board member protagonist therapeutics william d waddill board member protagonist therapeutics chaitan khosla board member protagonist therapeutics popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla daniel a dematteo executive chairman gamestop corp david j oconnor president and ceo the madison square garden company × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   patel phd dinesh  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors patel phd dinesh check out list of companies and businesses related to patel phd dinesh find out patel phd dinesh address and contact details view other people related to patel phd dinesh  coworkers colleagues companions etc address  adams drive suite  menlo business park menlo park  ca companies related to patel phd dinesh cikcompany namepositioncompany addressprotagonist therapeutics inc gateway blvd suite  newark  patel phd dinesh on the web persons related to patel phd dinesh  protagonist therapeutics incnamepositioncityadage capital advisors llcbostonadage capital partners gp llcbostonadage capital partners lpshanafelt armenmenlo parkshanafelt phd armenmilpitasxavier asishmenlo parkxavier phd asishmilpitasrobert atchinsonbostoncanaan partners x llcwestportcanaan x lpdirector westportpatel phd dineshmenlo parkpatel phd dineshmilpitasphillip grossbostonsteven edward hallcambridgeselick phd haroldmilpitasselick haroldmenlo parkwilliam a hoddersr vp  corporate development milpitasjohnson  johnson owner new brunswickjohnson  johnson development corp et alnew brunswickchaitan phd khosladirector lilly ventures fund i llcsan diegodavid y liuchief scientific officer milpitaslv management group llc owner indianapolispanaccio phd michaelmilpitaspeace nicholasmenlo parkthomas p oneilchief financial officer davisjulie papanekdirector milpitasdinesh v ph d patelpresident and ceo milpitastruex paulmilpitasharold e selickdirector redwood cityrichard s shamechief medical officer milpitasarmen shanafeltdirector indianapoliss edward torressan diegowilliam d waddilldirector redwood citylewis t williamsdirector brea dinesh v ph d patel  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors dinesh v ph d patel check out list of companies and businesses related to dinesh v ph d patel find out dinesh v ph d patel address and contact details view other people related to dinesh v ph d patel  coworkers colleagues companions etc address co protagonist therapeutics inc  cottonwood drive suite  milpitas  ca companies related to dinesh v ph d patel cikcompany namepositioncompany addressprotagonist therapeutics incpresident and ceo  gateway blvd suite  newark  dinesh v ph d patel on the web persons related to dinesh v ph d patel  protagonist therapeutics incnamepositioncityadage capital advisors llcbostonadage capital partners gp llcbostonadage capital partners lpshanafelt armenmenlo parkshanafelt phd armenmilpitasxavier asishmenlo parkxavier phd asishmilpitasrobert atchinsonbostoncanaan partners x llcwestportcanaan x lpdirector westportpatel phd dineshmenlo parkpatel phd dineshmilpitasphillip grossbostonsteven edward hallcambridgeselick phd haroldmilpitasselick haroldmenlo parkwilliam a hoddersr vp  corporate development milpitasjohnson  johnson owner new brunswickjohnson  johnson development corp et alnew brunswickchaitan phd khosladirector lilly ventures fund i llcsan diegodavid y liuchief scientific officer milpitaslv management group llc owner indianapolispanaccio phd michaelmilpitaspeace nicholasmenlo parkthomas p oneilchief financial officer davisjulie papanekdirector milpitasdinesh v ph d patelpresident and ceo milpitastruex paulmilpitasharold e selickdirector redwood cityrichard s shamechief medical officer milpitasarmen shanafeltdirector indianapoliss edward torressan diegowilliam d waddilldirector redwood citylewis t williamsdirector brea form  protagonist therapeutics for apr  filed by patel dinesh v ph d research stocks news story skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  news  events  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print format change text size default text sizea larger text sizea largest text sizea form  protagonist therapeutics for apr  filed by patel dinesh v ph d by k wizard—  pm et  httparchivefastedgarcomaszzcmuivwzjabkzrzp filed on april   more ptgx news ptgx has no more news copyright – fmr llc  all rights reserved  terms of use privacy security site map  stock market research top stocks quotes  news  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas you are here stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries stock research center not a fidelity customer no problem try our research for free without opening an account   trending stocks market movers top rated by sector orders by fidelity customers filters refresh equity summary score provided by starmine investing insights technical events provided by recognia as of  methodology recognia methodology bullish and bearish events of the day provide longshort trading ideas by identifying us stocks that have recently formed a bullish or bearish classic chart pattern patterns must have taken at least  days to form which draws out the more significant patterns for intermediate or longterm trend direction the list is then filtered to include stocks with a minimum  for bullish and  for bearish close price and a minimum  trading volume most recent patterns are listed first patterns on the same date are sorted using recognias proprietary quantitative algorithm to draw strong companies to the top and if further sorting is required for stocks with the same quantitative analysis result it is done by trading volume to draw highest volume stocks to the top bofi log in for events hafc an earn epam sn log in for events chkp lho fit gts find out how to use fundamental analysis and technical analysis when evaluating stocks with the help of the fidelity learning center my research –  organize and track your favorite securities get started todays events as of  am et  earnings  dividends  splits  upgrades  downgrades  economic  upcoming webinar events visit the learning center events page for a full list of upcoming webinars the equity summary score is provided for informational purposes only does not constitute advice or guidance and is not an endorsement or recommendation for any particular security or trading strategy the equity summary score is provided by thomson reuters starmine an independent company not affiliated with fidelity investmentsgics® global industry classification standards is an industry classification system developed by standard  poors in collaboration with morgan stanley capital international msci sp uses gics to determine the market segment to which a company is assignednews commentary including related symbols and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their usestock markets especially foreign markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments sector funds can be more volatile because of their narrow concentration in a specific industrysystem availability and response times may be subject to market conditionsthe fidelity screeners are research tools provided to help selfdirected investors evaluate securities the criteria and inputs entered are at the sole discretion of the user and all screens or strategies with preselected criteria are solely for the convenience of the user information supplied or obtained from the screeners is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell securities or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy or approach to screening or evaluating stocks preferred securities exchange traded products or closed end funds fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their use determine which securities are right for you based on your investment objectives risk tolerance financial situation and other individual factors and reevaluate them on a periodic basis copyright – fmr llc  all rights reserved  terms of use privacy security site map  ptgx stock news  fidelity skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print  helpglossary helpglossary news  eventsptgx protagonist therapeutics inc    as of am et  quotes delayed at least  min log in for real time quote add to watch list set alert hypothetical trade price history download to csv file download to excel file log in for more news expand all collapse all briefprotagonist therapeutics says board increased number of directors from six to seven  sec filing reuters –  am et  protagonist therapeutics inc ptgx  protagonist therapeutics ptgx  in connection with williamss appointment to cos board board increased number of directors from six to seven  sec filing source text for eikon further company coverage briefprotagonist therapeutics appoints five prime therapeutics ceo to board of directors reuters –  am et  protagonist therapeutics inc ptgx  protagonist therapeutics ptgx appoints five prime therapeutics ceo lewis t rusty williams to its board of directors source text for eikon further company coverage protagonist therapeutics appoints five prime therapeutics ceo lewis t rusty williams to its board of directors pr newswire –  am et  newark calif dinesh v patel phd president and chief executive officer of protagonist us stockswall st opens slightly lower as investors digest data reuters –  am et   april consumer spending biggest increase in four months  cardconnect ccn jumps  first data fdc to buy company for  mln  dow down  pct sp off  pct nasdaq up  pct by tanya agrawal us stocks opened slightly lower on tuesday after a threeday holiday weekend as oil prices fell and investors parsed a barrage of economic data for a reading on the health of the economy us stockswall st set to open lower as investors digest data reuters –  am et   april pce rises  pct vs fall of  pct in march  april consumer spending biggest increase in four months  cardconnect ccn jumps  first data fdc to buy company for  mln futures down dow  pts sp  pts nasdaq  pts by tanya agrawal briefprotagonist therapeutics says will be responsible for conduct of phase  clinical trial for ptg reuters –  am et  protagonist therapeutics inc ptgx  protagonist therapeutics inc ptgx says co will be responsible at its own expense for conduct of phase  clinical trial for ptg  sec filing  protagonist therapeutics inc ptgx  janssen will be responsible for conduct of a phase  clinical trial for ptg in cd briefprotagonist therapeutics signs deal with jj to develop bowel drug reuters –  am et  protagonist therapeutics inc ptgx  protagonist therapeutics enters into worldwide agreement with janssen to codevelop and commercialize ptg for inflammatory bowel disease  protagonist therapeutics to receive a  million upfront payment and potentially up to an additional  million in development and sales milestones protagonist therapeutics enters into worldwide agreement with janssen to codevelop and commercialize ptg for inflammatory bowel disease pr newswire –  am et  newark calif david y liu phd protagonists chief scientific officer and head of rd as evidenced by ptg we believe our technology platform is validated in its ability to generate potential firstinclass oral peptides as the next generation of targeted therapy drugs for ibd protagonist therapeutics initiates phase  study with novel hepcidin mimetic ptg pr newswire –  am et  newark calif dinesh v patel phd president and chief executive officer protagonist therapeutics ptgx the phase  single ascending dose study will evaluate the safety tolerability and pharmacokinetics of ptg in normal healthy volunteers briefprotagonist therapeutics receives  mln sbir funding for development of biomarkers reuters –  am et  protagonist therapeutics inc ptgx  protagonist therapeutics inc ptgx  receives  million sbir funding for development of biomarkers of il receptor antagonist activity  protagonist therapeutics inc ptgx  company expects to initiate human clinical testing of ptg in second half of  source text for eikon further company coverage protagonist therapeutics receives  million sbir funding for development of biomarkers of il receptor antagonist activity pr newswire –  am et  newark calif dinesh patel phd protagonist therapeutics president and chief executive officer briefprotagonist therapeutics reports qtrly net loss per share attributable to common stockholders  reuters –  pm et  protagonist therapeutics inc ptgx  protagonist therapeutics ptgx reports first quarter  financial results  qtrly net loss per share attributable to common stockholders   protagonist therapeutics ptgx  expects current capital resources will be sufficient to fund operations through ptg phase b topline data source text for eikon further company coverage protagonist therapeutics reports first quarter  financial results pr newswire –  pm et  milpitas calif dinesh v patel phd protagonist president and chief executive officer recent business highlights financial results protagonist reported a net loss attributable to common stockholders of  million for the first quarter of  as compared to a net loss attributable to common stockholders of  million for the same period of  key patent issues covering protagonist therapeutics oral peptide il receptor antagonists including the development candidate ptg pr newswire –  pm et  milpitas calif david liu phd protagonists chief scientific officer and head of rd inhibition of the il pathway is an effective therapeutic treatment for ibd as evidenced by a marketed injectable antibody drug for treatment of crohns disease page page  todays and upcoming events aug  ptgx to announce q earnings after market unconfirmed past events last  days may  shareholders meeting data provided by wall street horizon inc   technical events classic patterns past  days provided by recognia inc log in for trading events view all technical analysis in advanced chart technical analysis provided by trading central log in for trading events as with all your investments through fidelity you must make your own determination whether an investment is appropriate for you fidelity is not recommending or endorsing this security by making it available to customers you should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase before investing you should read the prospectus offering circular indenture or similar document carefully for a full description of the product including its features and risks to determine whether it is an appropriate investment for your investment objectives risk tolerance financial situation and other individual factors and be sure to reevaluate those factors on a periodic basisperformance data shown represents past performance which is no guarantee of future results current performance may be higher or lower than the performance data quoted yield and return will vary therefore you may have a gain or loss when you sell your sharesstock markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments growth stocks can be more volatile than other types of stocks value stocks can continue to be undervalued by the market for long periods of time foreign securities are subject to interestrate currencyexchangerate economic and political risks all of which are magnified in emerging markets illiquidity is an inherent risk associated with investing in real estate and reits there is no guarantee the issuer of a reit will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid closedend funds can trade at a discount to their nav shareholders of master limited partnerships may be treated as partners for tax purposes partnerships issue a schedule k form  rather than a form  form for tax purposes it lists the partners share of income deductions credits etc speak with your tax advisor to determine how this may affect you a royalty trust is a type of corporation mostly in the united states or canada usually involved in oil and gas production or mining royalty trusts may have special tax treatment so you should consult a tax advisor on the potential tax consequences of investing in themnews commentary and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their useany data charts and other information provided on this page are intended for research purposes to help selfdirected investors evaluate many types of securities including but not limited to common stocks american depository receipts master limited partnerships real estate investment trusts traditional preferred stock trust preferred securities thirdparty trust certificates convertible securities mandatory convertible securities and other exchangetraded equity andor debt securities criteria and inputs entered including the choice to make security comparisons are at the sole discretion of the user and are solely for the convenience of the user analyst opinions ratings and reports are provided by thirdparties unaffiliated with fidelity all information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell a security or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating individual securities fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from its use copyright – fmr llc  all rights reserved  terms of use privacy security site map  see the latest features personalizedget relevant information about your holdings right when you need itsee your performance click the portfolio icon to get information about stocks you own without leaving the research pagefaster access to positions a shortcut to view the full list of positions in your portfolio yes please use the ticker search boxadd your own notes use notebook to save your investment ideas in one convenient private and secure place convenient for youresearch thats clear accessible and all in one place makes for a better experienceonestop shop see everything you need to make investment decisions right in the dashboardaccess anywhere no matter where you are use the stock research experience across multiple devicesnew ideas on the ready find new ideas using quick links to the stock screener new ways to researchdiscover new tools to add or diversify your existing research strategystocktwits read live tweets from the financial and investing community about the stock youre interested infundamental analysis save time on research by getting an overall assessment of a companys valuation quality growth stability and financial healthrecognia technical analysis perfect for the technical trader—this indicator captures a stocks technical events and converts them into short medium and longterm sentimenttop competitors see how a stock measures up by instantly comparing it to the industry average and its top four competitorssocial sentiment get a sense of peoples overall feelings towards a company in social media with this summary toolearnings data monitor earnings expectations over the past three quarters and model a stocks price based on its pe dinesh patel  vspring capital  zoominfocom